Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer
NCT00086892Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jun 2004
- Primary completion
- Apr 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoints: Antitumor Activity and Toxicity. Started Jun 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00086892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086892.